Novartis' blockbuster-in-waiting, Entresto, has been handed its second big approval. The new heart failure drug has snagged an OK from the European Commission.
Genmab's plans to develop ofatumumab for lymphoma came to a halt as the company pulled the plug early on a Phase III trial that was unlikely to meet its goals, souring an investment from partner Novartis.
Novartis has been jockeying for additional uses for its next-gen psoriasis med, Cosentyx, hoping that a trifecta of indications will help generate blockbuster sales and distinguish the drug from its competition in a hot market. Now the med is moving one step closer toward achieving its blockbuster aspirations with an EU nod to treat patients with psoriatic arthritis and ankylosing spondylitis.
Bestselling asthma drugs from Novartis and respiratory behemoth GlaxoSmithKline are also showing more adverse events in post-marketing safety data than competing products from Merck, according to a new report, potentially presenting issues further down the line as companies duke it out for market share.
Novartis is moving toward the U.S. market with a biosimilar of Amgen's Neulasta, awaiting FDA approval for a long-acting treatment designed to boost white blood cell count.
Swiss drug giant Novartis says it has taken "remedical action" to correct problems at two of its plants in western India that were given a warning letter by the U.S. Food and Drug Administration, according to a report by NDTV.
Roche's Genentech is pairing up with Novartis to split the ex-U.S. rights to an Ophthotech eye drug, opting into an agreement that could be worth more than $1 billion.
Novartis India Managing Director Ranjit Shahani told India's PTI that the drugmaker expects upgrades at two Sandoz plants that were issued a warning letter by the FDA to soon be back to full production.
Japan's Ministry of Health, Labor and Welfare said a business improvement order was issued to the Japan unit of Swiss-based Novartis on Nov. 13 for failing to report unspecified drug side effects on time, the third such sanction for the company in 18 months.
Teva did everything in its power to block generic copies of lead drug Copaxone from hitting the market. But now that one is here--Novartis' Glatopa--the Israeli drugmaker's giant is faring better than industry watchers expected.